Navegar por autor "Fernández Montes, Ana"

Ascertaining breast cancer patient experiences through a journey map: A qualitative study protocol.

2020- Ciria-Suarez, Laura; Jiménez-Fonseca, Paula; Palacín-Lois, María; Antoñanzas-Basa, Mónica; Fernández Montes, Ana; [et al.]

Carcinoma microcítico de próstata. Una histología atípica

2011- Fernández Montes, Ana; Nuñez Viejo, Miguel Angel; Alonso Bermejo, Miguel Angel; García. Gómez, Jesús

Complicaciones de las endoprótesis metálicas autoexpandibles en la obstrucción maligna esofágica y gastroduodenal. Estudio de seis casos

2020- Nuñez Viejo, Miguel Angel; González Noya, Amara; Fernández Montes, Ana; Fernández-Carrera Soler, Jose Manuel

Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion.

2020- Fernández Montes, Ana; Grávalos, Cristina; Pericay, Carles; Safont, Ma José; Benavides, Manuel; [et al.]

Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

2019- Martinez Lago, Nieves Purificacion; Carmona Campos, Marta; Gonzalez Villarroel, P; Salgado Fernández, Mercedes; De La Cámara Gómez, Juan Cruz; [et al.]

Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers

2019- Fernández Montes, Ana; Martinez Lago, Nieves Purificacion; Covela Rúa, Marta; De La Cámara Gómez, Juan Cruz; González Villaroel, Paula; [et al.]

Eficacia, toxicidad y adherencia terapéutica de gefitinib en el tratamiento del cáncer de pulmón no microcítico

2012- Firvida Perez, Jose Luis; Pereira Vázquez, María; Fernández Montes, Ana; Castro Gómez, José Enrique; Nuñez Viejo, Miguel Angel; [et al.]

Erlotinib as frontline treatment for elderly patients (P) with advanced non-squamous non-small cell lung cancer (NSNSCLC): GGCP044/09 study

2012- Afonso Afonso, Francisco Javier; Fernández Calvo, Ovidio; Firvida Perez, Jose Luis; Areses Manrique, María Carmen; Fernández Montes, Ana; [et al.]

Erlotinib as frontline treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC) and non-squamous histology - Results of a galician lung cancer group (GGCP044/09 study) grupo galego de cancro de pulmon (GGCP)

2011- Firvida Perez, Jose Luis; Fernández Montes, Ana; Vázquez Estévez, Sergio; Varela Ferreiro, Silvia; Campos Balea, Begoña; [et al.]

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial

2019- Fernández Montes, Ana; Martinez Lago, Nieves Purificacion; De La Cámara Gómez, Juan Cruz; Covela Rúa, Marta; Cousillas Castiñeiras, A; [et al.]

Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study

2013- Valladares Ayerbes, Manuel; Reboredo Lopez, Margarita; Fernández Montes, Ana; Varela Ferreiro, Silvia; Quintero Aldana, Guillermo; [et al.]

Gemcitabine Plus Oral Vinorelbine as Salvage Therapy Treatment for Patients With Advanced Non-small-cell Lung Cancer and Squamous Histology - a Galician Lung Cancer Group Study (GGCP042/09) Grupo Galego De Cancro De Pulmon (GGCP)

2011- Firvida Perez, Jose Luis; Fernández Montes, Ana; Vázquez Estévez, Sergio; Varela Ferreiro, Silvia; Campos Balea, Begoña; [et al.]

Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease.

2020- Aparicio, Jorge; Esposito, Francis; Serrano, Sara; Falco, Esther; Escudero, Pilar; [et al.]

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

2022- Fernández Montes, Ana; Élez, E.; Vivancos, A.; Martínez, N.; González, P.; [et al.]

Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer

2015- Gallardo Martín , Maria Elena; Fernández Montes, Ana; Varela Ferreiro, Silvia; Campos Balea, Begoña; Álvarez Gómez, Elena; [et al.]

Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Study

2017-06-13- Vidal Insua, Yolanda; De La Cámara Gómez, Juan Cruz; Brozos Vázquez, Elena María; Fernández Montes, Ana; Vázquez Rivera, Francisca; [et al.]

Pro-COL11A1: A biomarker to predict malignant relapse of breast intraductal papillomas

2013- Fernández Montes, Ana

Retrospective analysis of prognostic and predictive markers in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nabpaclitaxel: Influence of the presence of stent

2015- Valladares Ayerbes, Manuel; Fernández Montes, Ana; Salgado Fernández, Mercedes; De La Cámara Gómez, Juan Cruz

Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry

2020- Cotes Sanchís, Almudena; Gallego, Javier; Hernandez, Raquel; Arrazubi, Virginia; Custodio, Ana; [et al.]

Survival of patients with high grade gliomas in our hospital

2013- Caramés Díaz, Nuria María; Castro Castro , Julian; Pastor Zapata, Ana; Fernández Montes, Ana; Castro Gómez, José Enrique; [et al.]

Repositorio digital RUNA

Navegar por autor "Fernández Montes, Ana"

Ascertaining breast cancer patient experiences through a journey map: A qualitative study protocol. ﻿

Carcinoma microcítico de próstata. Una histología atípica ﻿

Complicaciones de las endoprótesis metálicas autoexpandibles en la obstrucción maligna esofágica y gastroduodenal. Estudio de seis casos ﻿

Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. ﻿

Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen ﻿

Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers ﻿

Eficacia, toxicidad y adherencia terapéutica de gefitinib en el tratamiento del cáncer de pulmón no microcítico ﻿

Erlotinib as frontline treatment for elderly patients (P) with advanced non-squamous non-small cell lung cancer (NSNSCLC): GGCP044/09 study ﻿

Erlotinib as frontline treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC) and non-squamous histology - Results of a galician lung cancer group (GGCP044/09 study) grupo galego de cancro de pulmon (GGCP) ﻿

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial ﻿

Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study ﻿

Gemcitabine Plus Oral Vinorelbine as Salvage Therapy Treatment for Patients With Advanced Non-small-cell Lung Cancer and Squamous Histology - a Galician Lung Cancer Group Study (GGCP042/09) Grupo Galego De Cancro De Pulmon (GGCP) ﻿

Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease. ﻿

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer ﻿

Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer ﻿

Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Study ﻿

Pro-COL11A1: A biomarker to predict malignant relapse of breast intraductal papillomas ﻿

Retrospective analysis of prognostic and predictive markers in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nabpaclitaxel: Influence of the presence of stent ﻿

Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry ﻿

Survival of patients with high grade gliomas in our hospital ﻿

Ascertaining breast cancer patient experiences through a journey map: A qualitative study protocol.

Carcinoma microcítico de próstata. Una histología atípica

Complicaciones de las endoprótesis metálicas autoexpandibles en la obstrucción maligna esofágica y gastroduodenal. Estudio de seis casos

Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion.

Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers

Eficacia, toxicidad y adherencia terapéutica de gefitinib en el tratamiento del cáncer de pulmón no microcítico

Erlotinib as frontline treatment for elderly patients (P) with advanced non-squamous non-small cell lung cancer (NSNSCLC): GGCP044/09 study

Erlotinib as frontline treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC) and non-squamous histology - Results of a galician lung cancer group (GGCP044/09 study) grupo galego de cancro de pulmon (GGCP)

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial

Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study

Gemcitabine Plus Oral Vinorelbine as Salvage Therapy Treatment for Patients With Advanced Non-small-cell Lung Cancer and Squamous Histology - a Galician Lung Cancer Group Study (GGCP042/09) Grupo Galego De Cancro De Pulmon (GGCP)

Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease.

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer

Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Study

Pro-COL11A1: A biomarker to predict malignant relapse of breast intraductal papillomas

Retrospective analysis of prognostic and predictive markers in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nabpaclitaxel: Influence of the presence of stent

Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry

Survival of patients with high grade gliomas in our hospital